Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

UroVysion testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer.

Whitson JM, Berry AB, Carroll PR, Konety BR.

Int Braz J Urol. 2009 Nov-Dec;35(6):664-70; discussion 671-2.

2.

A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.

Whitson J, Berry A, Carroll P, Konety B.

BJU Int. 2009 Aug;104(3):336-9. doi: 10.1111/j.1464-410X.2009.08375.x. Epub 2009 Feb 10.

3.

Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.

Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, Blute MM, Lieber MM, Zincke H, Halling KC.

J Urol. 2005 Feb;173(2):401-4.

PMID:
15643180
4.

The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.

Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S.

J Urol. 2000 Sep;164(3 Pt 1):685-9.

PMID:
10953125
5.

The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.

Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K, Mattarelli G, Eichenberger T, Dalquen P, Spieler P, Schoenegg R, Gasser TC, Sulser T, Forster T, Zellweger T, Casella R, Bubendorf L.

Int J Cancer. 2009 Jun 15;124(12):2899-904. doi: 10.1002/ijc.24258.

6.

The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.

Solsona E, Iborra I, Rubio J, Casanova J, Almenar S.

BJU Int. 2004 Dec;94(9):1258-62.

7.

Diagnosis and management of superficial bladder cancer.

Amling CL.

Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. Review.

PMID:
11514784
8.

[Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer].

Li Q, Xu T, Wang XF.

Zhonghua Zhong Liu Za Zhi. 2009 Dec;31(12):904-7. Chinese.

PMID:
20193328
9.

The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.

Boorjian SA, Zhu F, Herr HW.

BJU Int. 2010 Aug;106(3):357-61. doi: 10.1111/j.1464-410X.2009.09137.x. Epub 2009 Dec 11.

11.
12.

Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.

Ray ER, Chatterton K, Khan MS, Chandra A, Thomas K, Dasgupta P, O'Brien TS.

BJU Int. 2010 Mar;105(6):789-94. doi: 10.1111/j.1464-410X.2009.08839.x. Epub 2009 Oct 13.

13.
14.

UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.

Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA.

Eur Urol. 2007 May;51(5):1275-80; discussion 1280. Epub 2006 Oct 30.

PMID:
17084511
15.

Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.

Bergman J, Reznichek RC, Rajfer J.

BJU Int. 2008 Jan;101(1):26-9. Epub 2007 Sep 10.

16.
17.

The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.

Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED.

Urol Oncol. 2004 Jan-Feb;22(1):16-9.

PMID:
14969798
18.

Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy.

Mengual L, Marín-Aguilera M, Ribal MJ, Burset M, Villavicencio H, Oliver A, Alcaraz A.

Eur Urol. 2007 Sep;52(3):752-9. Epub 2007 Mar 12.

PMID:
17379395
19.

Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test.

Raitanen MP, Hellström P, Marttila T, Korhonen H, Talja M, Ervasti J, Tammela TL; Finnbladder Group.

Eur Urol. 2001 Oct;40(4):422-6.

PMID:
11713397
20.

Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.

Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R.

Urology. 2004 Mar;63(3):466-71.

PMID:
15028439
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk